Ipamorelin is just steroids with extra steps

The objection collapses two pharmacologies that share an end-goal (improved body composition or tissue repair) into a single category. The collapse is wrong on three load-bearing dimensions. First, the hormone in play. Anabolic steroids are exogenous androgens — testosterone or its synthetic derivatives — that bind the androgen receptor directly across muscle, bone, brain, and reproductive tissue. Ipamorelin is a ghrelin receptor agonist that triggers endogenous *growth hormone* release from pituitary somatotrophs, which in turn drives hepatic IGF-1 production. The two hormones do overlapping things at the level of muscle protein synthesis, but they are different molecules acting on different receptors with different downstream cascades. Treating them as interchangeable misses the basic pharmacology. Second, the temporal pattern. Anabolic steroids in typical dosing produce sustained supraphysiological androgen exposure; the suppression of endogenous testosterone production via HPG-axis feedback is the well-characterized consequence and the source of the long-term endocrine concerns. Ipamorelin's effect, by contrast, is *pulsatile* — the foundational selectivity story (Raun et al., *Eur J Endocrinol* 1998) is that it produces a GH pulse comparable to physiological pulsatile release rather than a tonic elevation. Pulsatility is part of what differentiates the safety profile. Third, the off-target endocrine effects. Anabolic steroid use has well-documented effects on lipid profiles, hepatic function, cardiovascular structure, and mood — through both direct androgen-receptor activity and downstream estrogen conversion. The Raun 1998 paper specifically demonstrated that Ipamorelin does *not* meaningfully elevate ACTH, cortisol, prolactin, FSH, LH, or TSH at doses 200-fold above the GH-release threshold. That clean selectivity is the reason Ipamorelin became the practitioner default among GH secretagogues; earlier-generation GH-releasing peptides (GHRP-6, GHRP-2) raised cortisol and prolactin in parallel and carried more of the "extra steps" the objection describes. Where the critic has a real point: any GH-axis intervention raises IGF-1, and chronic IGF-1 elevation carries the same cancer-mechanism caution that applies to anabolic steroid use, growth-hormone replacement, and the broader class of GH-axis pharmacology. The cancer-prone populations who should not consider Ipamorelin are largely the same as those who should not consider exogenous testosterone. On that single dimension, the objection is gesturing at a real shared concern. Where the critic loses the thread: across receptor biology, temporal pattern, and off-target endocrine effects, Ipamorelin and anabolic steroids are *different drugs*. Conflating them obscures the question that actually matters — what does long-term selective GH-axis activation do that long-term androgen exposure does not? — and replaces it with a category-error rhetoric that doesn't survive the basic pharmacology.